ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.672,86
-0,29%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,00%
Euro vs US Dollar
1,083
-0,23%
Bitcoin
70.023,65
-0,15%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Genuit Group Plc (GEN)

  7. Genuit Group Plc (GEN) News

GEN

Genuit (GEN)

Genuit Group Plc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:GEN
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202409h00PR Newswire (US)Deepfakes, AI-Manipulated Audio, and Hijacked Social Media Surge in 2024LSE:GENGenuit Group Plc
02/05/202417h57RNS Regulatory NewsGenuit Group PLC Block listing Interim ReviewLSE:GENGenuit Group Plc
24/04/202411h39RNS Regulatory NewsGenuit Group PLC Notice of AGMLSE:GENGenuit Group Plc
10/04/202417h24RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
10/04/202417h17RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
09/04/202417h28RNS Regulatory NewsGenuit Group PLC Director DeclarationLSE:GENGenuit Group Plc
02/04/202416h56RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
20/03/202416h27RNS Regulatory NewsGenuit Group PLC Director/PDMR ShareholdingLSE:GENGenuit Group Plc
12/03/202411h40Alliance NewsAlliance NewsGenuit revenue drops on lower divisional sales but profit surgesLSE:GENGenuit Group Plc
12/03/202408h09Alliance NewsAlliance News*Genuit says 2024 trading has started in line w/ expectations, despite market uncertaintyLSE:GENGenuit Group Plc
12/03/202408h09Alliance NewsAlliance News*Genuit declares total dividend per share of 12.4p vs 12.3p YoYLSE:GENGenuit Group Plc
12/03/202408h07Alliance NewsAlliance News*Genuit 2023 pretax profit GBP48.4m vs GBP45.4m YoYLSE:GENGenuit Group Plc
12/03/202408h00RNS Regulatory NewsGenuit Group PLC Final ResultsLSE:GENGenuit Group Plc
01/03/202409h30RNS Regulatory NewsGenuit Group PLC Director DeclarationLSE:GENGenuit Group Plc
19/02/202410h00RNS Regulatory NewsGenuit Group PLC Notice of Results and Investor PresentationLSE:GENGenuit Group Plc
23/01/202416h49UK RegulatoryGenuit Group PLC Holding(s) in CompanyLSE:GENGenuit Group Plc
23/01/202412h24UK RegulatoryGenmab A/S Genmab Announces Net Sales Of Darzalex(R) (daratumumab) For 2023LSE:GENGenuit Group Plc
23/01/202400h40UK RegulatoryGenmab A/S Genmab Announces Decision In Arbitration Appeal Under License Agreement With JanssenLSE:GENGenuit Group Plc
09/01/202412h45UK RegulatoryGenmab A/S Tivdak(R) (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted For Priority Review By U.S. Food And Drug Administration For Patients With Recurrent Or Metastatic Cervical CancerLSE:GENGenuit Group Plc
03/01/202406h55UK RegulatoryGenmab A/S Transactions With Shares And Linked Securities In Genmab A/S Made By Managerial Employees And Their Closely Associated PersonsLSE:GENGenuit Group Plc
02/01/202415h52UK RegulatoryGenmab A/S Genmab To Present At The 42nd Annual J.P. Morgan Healthcare ConferenceLSE:GENGenuit Group Plc
12/12/202313h00UK RegulatoryGenmab A/S Genmab To Hold 2023 R&D Update And Ash Data Review MeetingLSE:GENGenuit Group Plc
09/12/202318h00UK RegulatoryGenmab A/S New Pivotal Data For Bispecific Antibody Epcoritamab (DuoBody(R) Cd3xcd20) Demonstrates High Overall And Complete Responses In Patients With Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)LSE:GENGenuit Group Plc
05/12/202323h26UK RegulatoryGenmab A/S Capital Increase In Genmab As A Result Of Employee Warrant ExerciseLSE:GENGenuit Group Plc
27/11/202313h00UK RegulatoryGenmab A/S Genmab Announces Positive Regulatory Updates For Epcoritamab (EPKINLY(R)/Tepkinly(R)) For The Treatment Of Relapsed/Refractory Follicular LymphomaLSE:GENGenuit Group Plc
22/11/202308h00UK RegulatoryGenuit Group PLC Strategy Progress Update NotificationLSE:GENGenuit Group Plc
21/11/202322h45UK RegulatoryGenmab A/S Transactions With Shares And Linked Securities In Genmab A/S Made By Managerial Employees And Their Closely Associated PersonsLSE:GENGenuit Group Plc
21/11/202322h42UK RegulatoryGenmab A/S Grant Of Restricted Stock Units To Board Members And Employees And Grant Of Warrants To Employees In GenmabLSE:GENGenuit Group Plc
15/11/202310h03Alliance NewsAlliance NewsGenuit shares rise as annual profit predicted to exceed expectationsLSE:GENGenuit Group Plc
15/11/202308h00UK RegulatoryGenuit Group PLC Trading UpdateLSE:GENGenuit Group Plc
 Showing the most relevant articles for your search:LSE:GEN

Kürzlich von Ihnen besucht

AMEX
XLF
Financial Select Sector
NYSE
KO
Coca Cola
TG
TUI1
Tui
TG
BAS
BASF
COIN
ETHUSD
Ethereum
COIN
BTCUSD
Bitcoin
TG
CBK
Commerzbank
USOTC
BNPQY
BNP Paribas (QX)
DBI
MDAX
MDAX
DBI
TDXP
Tec DAX
TG
BAYN
Bayer
NASDAQ
AAPL
Apple
NASDAQ
NVDA
NVIDIA
PM
XAUUSD
Gold vs US Dollar
USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten